Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders

被引:16
作者
Brown, Jennifer R. [1 ,2 ]
Neuberg, Donna [3 ]
Phillips, Kimberly
Reynolds, Hazel
Silverstein, Jason
Clark, Jennifer C.
Ash, Megan
Thompson, Christina
Fisher, David C. [2 ]
Jacobsen, Eric [2 ]
LaCasce, Ann S. [2 ]
Freedman, Arnold S. [2 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
familial lymphoma; familial chronic lymphocytic leukaemia; heritable; lifetime risk;
D O I
10.1111/j.1365-2141.2008.07355.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasing evidence points to a heritable contribution in the development of lymphoma. The goal of this study was to determine the rate of familial lymphoproliferative malignancy among consecutive lymphoma patients presenting to a tertiary care center and to enrol families with multiple affected first-degree relatives on a data and tissue collection study. Beginning in 2004 all new patients presenting to the Dana-Farber Cancer Institute with non-Hodgkin (NHL) or Hodgkin lymphoma (HL) or chronic lymphocytic leukaemia (CLL) were asked to complete a one-page self-administered family history questionnaire. 55.4% of 1948 evaluable patients reported a first-degree relative with a malignancy, with the highest rate among CLL probands. Lymphoid malignancies were particularly common, with 9.4% of all probands reporting a first-degree relative with a related lymphoproliferative disorder (LPD). This frequency was again highest for CLL, at 13.3% of CLL probands, compared to 8.8% of NHL probands and 5.9% of HL probands (P = 0.002). The prevalence of CLL was significantly increased in parents of CLL probands (P < 0.05), and a greater risk of NHL was seen in fathers of NHL probands than in mothers (P = 0.026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 45 条
[41]  
Verkasalo PK, 1999, INT J CANCER, V83, P743, DOI 10.1002/(SICI)1097-0215(19991210)83:6<743::AID-IJC8>3.0.CO
[42]  
2-Q
[43]   Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph) [J].
Wang, Sophia S. ;
Slager, Susan L. ;
Brennan, Paul ;
Holly, Elizabeth A. ;
De Sanjose, Silvia ;
Bernstein, Leslie ;
Boffetta, Paolo ;
Cerhan, James R. ;
Maynadie, Marc ;
Spinelli, John J. ;
Chiu, Brian C. H. ;
Cocco, Pier Luigi ;
Mensah, Fiona ;
Zhang, Yawei ;
Nieters, Alexandra ;
Dal Maso, Luigino ;
Bracci, Paige M. ;
Costantini, Adele Seniori ;
Vineis, Paolo ;
Severson, Richard K. ;
Roman, Eve ;
Cozen, Wendy ;
Weisenburger, Dennis ;
Davis, Scott ;
Franceschi, Silvia ;
La Vecchia, Carlo ;
Foretova, Lenka ;
Becker, Nikolaus ;
Staines, Anthony ;
Vornanen, Martine ;
Zheng, Tongzhang ;
Hartge, Patricia .
BLOOD, 2007, 109 (08) :3479-3488
[44]  
WATERHOUSE D, 1995, CANCER, V77, P763
[45]  
Zaizov-Marx R, 2003, BLOOD, V102, p897A